Zulvac 1 Ovis


inactivated bluetongue virus, serotype-1

This medicine is now withdrawn from use in the European Union.


The marketing authorisation for Zulvac 1 Ovis has been withdrawn at the request of the marketing-authorisation holder.

This EPAR was last updated on 01/04/2020

Authorisation details

Product details
Zulvac 1 Ovis
Agency product number
Active substance
inactivated bluetongue virus, serotype-1
International non-proprietary name (INN) or common name
inactivated bluetongue virus, serotype-1
Anatomical therapeutic chemical veterinary (ATCvet) codes
Accelerated assessmentAccelerated assessment

This medicine had an accelerated assessment. This means that it is a medicine of major interest for public health, so its timeframe for review was 150 evaluation days rather than 210. For more information, see Accelerated assessment.

Publication details
Marketing-authorisation holder
Zoetis Belgium SA
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Rue Laid Burniat 1
1348 Louvain-la-Neuve

Product information

21/06/2019 Zulvac 1 Ovis - EMEA/V/C/002335 - IB/00017

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group


Therapeutic indication

Active immunisation of sheep from 1.5 months of age for the prevention of viraemia caused by bluetongue virus, serotypes-1.

Onset of immunity: 21 days after completion of the primary vaccination scheme.

Duration of immunity: 12 months.

Assessment history

How useful was this page?

Add your rating